Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

New directions in bicyclopentane research

Objectif

The pharmaceutical industry is increasingly seeking new tactics for the structural modification of drug candidates to avoid metabolic susceptibility, or to improve pharmacokinetic properties. Analogues called 'bioisosteres', which mimic the dimensions and substituent directionality of problematic structural motifs, but which are not themselves subject to the same pharmacological issues, offer one solution. Often based on scaffolds not found in ‘typical’ drug candidates, bioisosteres can additionally occupy new areas of intellectual property space. Within this growing field, rigid polycycles such as bicyclo[1.1.1]pentane (BCP) are receiving significant attention as arene bioisosteres, as they exhibit similar ring diameters and substituent positioning, and also improve many pharmacokinetic properties relative to the parent arene. Despite the attractive nature of these motifs and current interest, the lack of general routes to complex BCP ring systems means this template is not yet fully accessible to industry. The invention of mild methods for [1.1.1.0]tricyclopentane (TCP) ring opening and functionalization could revolutionize use of BCPs in the pharmaceutical sector.
One method not explored to date is an atom transfer radical addition reaction (ATRA) strategy. Using aryl or alkyl halides, ATRA could deliver an abundance of previously inaccessible polysubstituted BCPs from generalized TCP, which would revolutionize this immature, cutting-edge area of organic and medicinal chemistry.
This research proposal seeks to: i) explore general and mild ATRA-based syntheses of BCP derivatives, including ring-expanded (hetero)bioisosteres; ii) functionalize BCP products using a range of contemporary processes, including C–H or C–X activation; and iii) apply these methodologies to synthesize BCP drugs / natural product analogues, and to test their biological activity via an industrial collaboration.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

MSCA-IF-EF-ST - Standard EF

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) H2020-MSCA-IF-2017

Voir tous les projets financés au titre de cet appel

Coordinateur

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Contribution nette de l'UE
€ 183 454,80
Adresse
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
Royaume-Uni
Région
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 183 454,80